Skip to main content

Table 4 Overview of the haematologic parameters measured in the first part of the study at week 16. The ranges mark the 95% confidence intervals

From: Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats

 PlaceboEverolimusPlacebo + [177Lu]Lu-DOTA-TATEEverolimus + [177Lu]Lu-DOTA-TATE
RBC (1012/l)8.33 ± 0.209.44 ± 0.458.05 ± 0.208.84 ± 0.35
Haemoglobin (g/l)144 ± 3163 ± 7138 ± 2153 ± 4
Haematocrit0.442 ± 0.0070.500 ± 0.0220.431 ± 0.0110.470 ± 0.016
Reticulocytes (‰)20.5 ± 3.323.6 ± 2.521.8 ± 2.223.1 ± 3.6
Platelets (109/l)597 ± 103544 ± 118545 ± 111506 ± 137
WBC (109/l)4.98 ± 0.864.49 ± 0.484.94 ± 0.614.16 ± 0.63
 Neutrophils0.81 ± 0.351.00 ± 0.300.71 ± 0.150.89 ± 0.13
 Monocytes0.12 ± 0.060.13 ± 0.070.17 ± 0.090.15 ± 0.10
 Lymphocytes4.03 ± 0.653.34 ± 0.484.03 ± 0.593.09 ± 0.57